Tissue Regenix USA Appoints VP of Operations

RNS Number : 8942K

Tissue Regenix Group PLC

05 August 2013

 



Tissue Regenix appoints Tim Buechner as Vice President of Operations of USA subsidiary Tissue Regenix Wound Care Inc

YORK, 5 August, 2013 - Tissue Regenix ('TRX'), the regenerative medical devices company, has appointed Tim Buechner as Vice President of Operations for its USA subsidiary; Tissue Regenix Wound Care Inc. Tim will work with Greg Bila to lead the development and expansion of Tissue Regenix's operations in the United States.

Tim joins Tissues Regenix most recently from KCI where he was Senior Director of Commercial and Sales Operations.  He has over twenty five years of experience across many disciplines including contracting, revenue cycle, sales operations, finance and project management.

In the past, Tim has held positions with United Parcel Service, the Veteran's Administration and the United States Air Force.  He has managed major organisational initiatives and has extensive experience with developing new business units and processes.

Tissue Regenix is currently establishing a new head office  in San Antonio, to facilitate the next phase of its expansion which will see the company collaborating with more research and clinical partners to expand the range of treatments using the dCELL® process.  Tim will be responsible for developing an agile infrastructure for the organisation that is capable of supporting the needs of the business and is customer-centric.

Tissue Regenix Wound Care Inc was established in November 2012 and has made a series of senior appointments from across the USA healthcare sector to build an experienced team to lead the company's development.

The first phase of this plan has seen Tissue Regenix, in June, sign a partnership with Community Tissue Services (CTS), the second largest tissue bank in the USA,  to develop dCELL® dermis products to target the wound care market. Chronic wounds affect 6.5 million patients in the USA at a cost of care greater than $25bn, and the partnership between CTS and Tissue Regenix will allow the company's dCELL® technology to revolutionise treatment of patients. It follows a similar agreement signed in the UK with the NHSBT which is using Tissue Regenix' dCELL® technology to develop dermis woundcare treatments.

Tissue Regenix also has a long-standing research collaboration with Dr Alan Dardik, Associate Professor of Vascular Surgery at Yale University, to develop vascular patches; and with Professor Francisco da Costa from the Pontifical University of Panama to commercialise dCELL® Heart Valves and facilitate the Company's entry into the $1.0bn global tissue heart valve market.

Greg Bila, President Tissue Regenix USA Inc commented: "We are delighted Tim has joined Tissue Regenix at this important point in our development. Since we established the USA business just eight months ago, we have made significant progress and the partnership with CTS enables us to move the business forward into full commercialisation, and use dCELL® to develop dermis treatments for use in skin graft operations.

"We are confident that with Tim's experience and contacts within the US healthcare sector he will play a valuable role in opening up new commercialisation partnerships for Tissue Regenix."

Antony Odell, Managing Director of Tissue Regenix Group Plc said: "Tim joins a strong management team who are driving Tissue Regenix's business growth and partnership development programme in the USA. Whilst we only established Tissue Regenix Wound Care Inc in November, we have worked for around three years with research partners at Yale University developing treatments for USA and global markets. Our latest partnership with CTS to produce dermis skin-grafts, plus the work with Yale on vascular patches (which have already achieved European CE marking) and the very promising work on heart valves with the Pontifical University of Parana means we are at an advanced stage in developing a range of treatments using dCELL® technology, giving access to markets worth hundreds of millions of dollars.

"We feel sure that Tim joining Tissue Regenix Wound Care Inc will help the team continue their rapid progress."

The dCELL® process removes DNA and other cellular material from animal and human tissue, leaving an inert, acellular tissue scaffold which can be used to repair damaged organs and tissues, while dramatically cutting the risk of rejection by the patient's body.

Tissue Regenix is currently focusing on four product areas; woundcare, cardiac, vascular and orthopaedic.

ENDS

For Further Information

Tissue Regenix Wound Care Inc:                                              [phone]

Greg Bila

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        [phone]

Alistair Kellie                                                                                   

Andrew Adie    

Andrew Jones                                                                  

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group Plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

NRALLFLRTVIFIIV